Astraea Therapeutics, LLC

Mountain View, CA 94043

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $4.79MM
First Award Date 07/01/10
Most Recent Award Date 06/01/17

Key Personnel

Last Name Name Awards Contact
Zaveri Nurulain T Zaveri 9

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 06/01/17 - 05/31/18

? DESCRIPTION (provided by applicant): Every year, about 100 million adult Americans experience some form of pain, a condition that costs the nation between $560 billion and $635 billion annually in lost productivity and treatment. The recently released `National Pain Strategy' developed by the NINDS's IPRCC, recognizes acute and chronic pai...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 06/01/16 - 05/31/17

? DESCRIPTION (provided by applicant): Every year, about 100 million adult Americans experience some form of pain, a condition that costs the nation between $560 billion and $635 billion annually in lost productivity and treatment. The recently released `National Pain Strategy' developed by the NINDS's IPRCC, recognizes acute and chronic pain...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/28/15 - 09/27/17

The long-term objective of this project is the discovery and development of novel high affinity and selective nociceptin opioid receptor (NOP) agonists that can be advanced into human clinical testing for alcoholism. While NOP agonists have not yet been clinically investigated for alcohol dependence, there is significant pharmacological evidence...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/01/15 - 05/31/16

DESCRIPTION (provided by applicant): The goal of the proposed Phase II SBIR is to advance a novel class of alpha3beta4 nicotinic acetylcholine receptor antagonists (new molecular entities), which show excellent in vivo efficacy in blocking nicotine self- administratio and reinstatement of nicotine seeking, towards development as smoking cessati...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/01/15 - 05/31/17

DESCRIPTION (provided by applicant): The goal of the proposed Phase II SBIR is to advance a novel class of alpha3beta4 nicotinic acetylcholine receptor antagonists (new molecular entities), which show excellent in vivo efficacy in blocking nicotine self- administratio and reinstatement of nicotine seeking, towards development as smoking cessati...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/01/14 - 05/31/15

DESCRIPTION (provided by applicant): The goal of the proposed Phase II SBIR is to advance a novel class of alpha3beta4 nicotinic acetylcholine receptor antagonists (new molecular entities), which show excellent in vivo efficacy in blocking nicotine self- administratio and reinstatement of nicotine seeking, towards development as smoking cessati...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/12 - 05/31/13

DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is associated with severe pain, which remains a major challenge to treat. Opioids are the current standard of care, but due to side effects and development of tolerance and dependence, remain a sub-optimal approach to treat SCD pain, particularly when used on a continued basis. Sickl...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): The overall goal of this SBIR Phase I project is to identify at least two suitable, efficacious preclinical candidates from our novel series of very potent and highly selective 34 nicotinic acetylcholine receptor (nAChR) ligands, for further translational development into smoking cessation medications. The pr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-OD-09-009
Budget: 07/01/10 - 06/30/12

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is one of the more common and serious neurodegenerative diseases characterized by degeneration of dopaminergic neurons in the brain, resulting in debilitating motor deficits such as tremor, rigidity, and akinesia, which have a severe impact on the patient as well as society. Dopamine ...